- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06340503
Evaluating a Physical Activity Index for Assessment and Counseling for Breast and Colon Cancer Survivors
March 25, 2024 updated by: Wake Forest University Health Sciences
Evaluating a Physical Activity Index for Assessment and Counseling for Breast and Colon Cancer Survivors in Clinical Practice
The purpose of this research study is to determine whether using the physical activity index screener, exercise coaching, and self-monitoring will increase physical activity and reduce time spent sitting or being inactive in patients who had breast or colon cancer.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
- Device: Research-grade accelerometer
- Other: National Comprehensive Cancer Network (NCCN) Education Materials
- Device: Garmin Vivofit activity tracker
- Other: Exercise Consultation Calls
- Other: Interview
- Other: Physical Activity Index Assessment (Intervention Arm)
- Other: Health Surveys
- Other: Physical Activity Index Assessment (Control Arm)
Detailed Description
To assess the feasibility (participation rate, adherence, and retention) of the Physical Activity Index (PAI) intervention in breast and colon cancer survivors supported by exercise coaching and self-monitoring tools.
Study Type
Interventional
Enrollment (Estimated)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Principal Investigator
- Phone Number: 336-716-3324
- Email: sbluethm@wakehealth.edu
Study Locations
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center
-
Contact:
- Principal Investigator
-
Principal Investigator:
- Shirley Bluethmann, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Survivors of breast or colon cancer (stages 0-III) diagnosed within the last three years prior to enrollment.
- Completed primary treatment (surgery, chemotherapy, and/or radiation) at least 3 months prior to enrollment.
- At least 50 years of age or older.
- Access to internet or cellular plan for video calls.
- Being willing and able to comply with the approved protocol and able to be to sign an IRB-approved informed consent document directly.
- Able to read and speak English
Exclusion Criteria:
- Participants with metastatic disease.
- Participants with recurrence or diagnosis of a different cancer.
- Participants receiving treatment other than maintenance therapy for their primary cancer (breast or colon).
- Participants has prior conditions that contraindicate exercise as determined by treating physician.
- Participants has gross cognitive impairment as determined by treating physician.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Patient Intervention Arm
Participants randomized into the intervention arm will receive a pre-exercise screening call about two weeks after enrolling into the study and complete the six (6) study visits and pre-determined test and procedures for the patient intervention arm.
|
Participants will be instructed to wear device for 7 days prior to each visit and to bring the device to each visit.
Study staff will extract data from the device within 14 days after each appointment and return the device to patients by mail.
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are comprised of recommendations for the prevention, diagnosis, and management of malignancies across the continuum of care.
This device can automatically capture and classify different physical activities such as walking, running, biking, swimming and using an elliptical.
The intervention group will receive five monthly exercise consultation calls with an exercise coach in between clinical visits and be provided with an exercise log for their personal use
The interviews will be conducted by a trained Q-PRO interviewer and audio recorded.
Interviews are expected to last approximately 30 minutes.
Discussion will include acceptability of the PAI intervention, related tools, and clinical experiences and will help shape/inform refinements need for a larger efficacy trial
Assessment will capture frequency and time spent in strenuous, moderate, and mild PA over the past 7 days.
Survivors also report hours of TV or similar sedentary screen time per week as a measure of sedentary behavior.
Completed at months 1, 3, 6, 9 and 12 while on study
Various health surveys will be completed to assess participant health and physical activities.
|
Active Comparator: Waitlist Control Arm
Participants randomized to the waitlist control arm, will have vitals collected and complete surveys at the first (baseline), 3-month, and 6-month visits pre-determined test and procedures for the waitlist control arm.
The pre-exercise consultation will begin after the 6-month visit.
|
Participants will be instructed to wear device for 7 days prior to each visit and to bring the device to each visit.
Study staff will extract data from the device within 14 days after each appointment and return the device to patients by mail.
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are comprised of recommendations for the prevention, diagnosis, and management of malignancies across the continuum of care.
This device can automatically capture and classify different physical activities such as walking, running, biking, swimming and using an elliptical.
The interviews will be conducted by a trained Q-PRO interviewer and audio recorded.
Interviews are expected to last approximately 30 minutes.
Discussion will include acceptability of the PAI intervention, related tools, and clinical experiences and will help shape/inform refinements need for a larger efficacy trial
Various health surveys will be completed to assess participant health and physical activities.
Assessment will capture frequency and time spent in strenuous, moderate, and mild PA over the past 7 days.
Survivors also report hours of TV or similar sedentary screen time per week as a measure of sedentary behavior.
Completed at months 6, 9 and 12 while on study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Eligible Participants - Participation Rate
Time Frame: 12 months
|
Participation will be measured by the number of eligible participants who agree to participate.
Investigators will calculate 95% confidence interval for each of the feasibility measures to determine the range of estimates that are consistent with the data.
|
12 months
|
Percentage of Participants to Complete Exercise Sessions - Adherence
Time Frame: 12 months
|
Adherence will be measured by the percent of participants who complete at least 3 out 5 exercise sessions.
Investigators will calculate 95% confidence interval for each of the feasibility measures to determine the range of estimates that are consistent with the data.
|
12 months
|
Number of Participants Who Complete Study Questionnaires - Retention
Time Frame: At baseline and up to 12 months
|
Retention will be defined as the number of participants who complete study questionnaires at baseline and one follow-up timepoint.
Investigators will calculate 95% confidence interval for each of the feasibility measures to determine the range of estimates that are consistent with the data.
|
At baseline and up to 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
July 1, 2024
Primary Completion (Estimated)
July 1, 2025
Study Completion (Estimated)
August 1, 2025
Study Registration Dates
First Submitted
March 25, 2024
First Submitted That Met QC Criteria
March 25, 2024
First Posted (Actual)
April 1, 2024
Study Record Updates
Last Update Posted (Actual)
April 1, 2024
Last Update Submitted That Met QC Criteria
March 25, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00111331
- P30CA012197 (U.S. NIH Grant/Contract)
- WFBCCC 01123 (Other Identifier: Atrium Health Wake Forest Baptist Comprehensive Cancer Center)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
Clinical Trials on Research-grade accelerometer
-
The University of Texas Medical Branch, GalvestonMohammad Zaidan, MDRecruiting
-
University of Wisconsin, MadisonNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...Completed
-
University of Texas Southwestern Medical CenterSouthern Methodist UniversityRecruiting
-
University of East AngliaUnknown
-
University Hospital, LimogesRecruiting
-
PepsiCo Global R&DCompletedSleep Quantity | Sleep EfficiencyUnited States
-
University of Alabama at BirminghamWithdrawnCardiovascular Diseases | Exercise | Sickle Cell Disease
-
University of MinnesotaTerminatedAnesthesiaUnited States
-
Ann & Robert H Lurie Children's Hospital of ChicagoUnknownPhysical Activity | SurgeryUnited States
-
Mayo ClinicJR Albert FoundationCompleted